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OBJECTIVE—To assess change in patient-reported outcomes in subjects with type 2 diabetes
treated with exenatide once weeklycompared with those treated with sitagliptin or pioglitazone.
RESEARCH DESIGN AND METHODS—In this 26-week randomized, multicenter,
double-dummy study, 491 subjects received 2 mg of exenatide once weekly or maximum daily
doses of sitagliptin (100 mg) or pioglitazone (45 mg) on a background of metformin. Weight-
related qualityof life,health utility, psychologicalwell-being,and diabetestreatment satisfaction
were assessed at baseline and week 26. Mean group changes from baseline to week 26 were
estimated by ANCOVA.
RESULTS—Weight-related quality of life total scores improved signiﬁcantly in the exenatide
onceweeklyandsitagliptinarmsonly;theexenatideonceweeklygroupexperiencedsigniﬁcantly
greaterimprovementthanthepioglitazonegroupinweight-relatedqualityoflifetotalscoresand
in several domain scores. Health utility scores improved signiﬁcantly for exenatide once weekly
and sitagliptin groups (P , 0.05) with no signiﬁcant difference between the exenatide once
weeklygroupandeithercomparisongroup.Allgroupsexperiencedsigniﬁcantimprovementson
thepsychologicalwell-beingglobalscale and all sixdomainscores, withno signiﬁcant difference
between the exenatide once weekly group and either comparator. All groups experienced sig-
niﬁcant improvements in total diabetes treatment satisfaction scores. The exenatide once weekly
group experienced greater improvement than the sitagliptin group in treatment satisfaction total
scores.
CONCLUSIONS—In combination with clinical outcomes from this study, these results in-
dicateitispossibleforpatientstreatedwithmetformintoinitiateexenatidetherapywithpotential
beneﬁts in both clinical and patient-reported outcomes.
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I
n the past decade, several new classes of
medication for type 2 diabetes have been
introduced, including thiazolidinediones
(TZD), glucagon-like peptide ago-
nists (GLP-1 agonists), and dipeptidyl
peptidase IV inhibitors (DPP-IV inhibi-
tors). Each class of agents affects blood
glucose control through different mecha-
nisms, and each class has different effects
onglucose proﬁles andonotherimportant
clinical outcomes such as weight (1).
Weight is a critically important issue in
patients with type 2 diabetes because
over 50% of them are obese (2), and for
these patients obesity exacerbates meta-
bolic problems, leading toincreased mor-
bidity and mortality (3). Unfortunately,
some medications that are effective in
controlling glycemia may also contribute
to weight gain (4).
Diabetesmedicationsdiffer notonlyin
theirclinical effects, but also intheir effects
on patient-reported outcomes (PROs)
such as general health utility, health-
relatedqualityoflife(QOL),psychological
well-being, and treatment satisfaction.
Health utility, QOL, and emotional well-
being are critical outcomes in their own
right, and treatment satisfaction can in-
ﬂuence clinical outcomes via its effect on
treatment adherence (5). Measures spe-
ciﬁc to important potential intervention
effects (e.g., a measure of weight-related
QOL), and disease-speciﬁcm e a s u r e s( e . g . ,
a measure of diabetes treatment satisfac-
tion) are generally considered more sensi-
tive than genericmeasures to the predicted
effects of clinical trial interventions (6).
Assessment of PRO is increasingly rec-
ognized as important in determining the
efﬁcacyofnewtherapies(7,8),yetwecould
ﬁnd few studies of TZD or GLP-1 receptor
agonists that considered these outcomes
(9–13), no such studies of DPP-IV inhibi-
tors, and no studies that compared agents
in these classes with each other. Thisstudy
is the ﬁrst to assess a broad range of PROs,
including health utility, weight-related
QOL,psychologicalwell-being, and diabe-
testreatment satisfaction,ina fully blinded
randomized clinical trial of patients treated
with agents from three commonly used
classes of oral diabetes medication (exe-
natide once weekly [exenatide QW],sita-
gliptin, and pioglitazone) who are also
taking metformin.
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ORIGINAL ARTICLEIn this study, we attempted to de-
termine whether exenatide treatment af-
fected patient-reported health utility,
weight-related QOL, psychological well-
being, and diabetes treatment satisfaction,
and whether changes in these PROs were
different for patients taking exenatide QW
from those for patients taking sitagliptin
or pioglitazone. Because all study subjects
took injections of active drug or placebo,
andgiventheknowneffectsofthesedrugs
on glycemic control and weight, we hy-
pothesize that PRO changes during the
study will be more favorable in patients
taking exenatide than in those taking sita-
gliptin or pioglitazone.
RESEARCH DESIGN AND
METHODS—Thisrandomized,double-
blind, double-dummy, multicenter clini-
cal trial was conducted at 72 sites with
514 patients in the U.S., India, and Mex-
ico. The study was designed to assess the
clinical outcomes, PROs, and safety of
26weeks oftreatmentwithexenatideQW
comparedwithmaximumapproveddoses
of sitagliptin or pioglitazone in patients
with type 2 diabetes treated with met-
formin. These medications address one or
both of the clinical issues (hypoglycemia
and weight) that have been raised as
concerns during intensive management
of patients with type 2 (14).
Eligible patients were male and non-
pregnant female patients, at least 18 years
of age, with type 2 diabetes, who were
treated with a stable regimen of metfor-
min monotherapy for a minimum of 2
months prior to screening. Additional
inclusion criteria included A1C 7.1–
11.0% and BMI 25–45 kg/m
2. Recruit-
ment occurred between February and
August of 2008.
Randomization and interventions
Patients were equally randomized to one
of three treatment groups: exenatide QW
(2mg)subcutaneousinjectiononceweekly
(self-administered) plus placebo oral cap-
sule each morning (QAM); sitagliptin
(100mg)QAMplusplacebosubcutaneous
injection self-administered once weekly;
pioglitazone (45 mg) QAM plus placebo
subcutaneous injection self-administered
once weekly. Randomization was stratiﬁed
according to country and screening A1C
stratum (,9.0 or$9.0%).Allpatients,the
study-site staff, the investigator, and the
sponsor were blinded to the identity of
study medication.
The appropriate ethical review board
at each site approved a common clinical
protocol. Patients provided written in-
formed consent prior to participation. The
study was conducted in accordance with
the principles described in the Declaration
of Helsinki, including all amendments
through the South Africa revision (15).
Primary study outcomes
The primary results of this 26-week study
for A1C, fasting plasma glucose, weight,
and adverse events are reported elsewhere
(16). Brieﬂy, the exenatide QW group
showed greater improvements in A1C
(21.55 vs. 20.92% for sitagliptin and
21.23% for pioglitazone; P , 0.05 for
both) and fasting plasma glucose (21.8
vs. 20.9 mmol/L for sitagliptin and –1.5
for pioglitazone; P , 0.05 for exenatide
vs. sitagliptin). Patients who received
exenatide QW experienced signiﬁcantly
greater reduction in weight (22.3 kg)
compared with those who received sita-
gliptin (20.8 kg) and pioglitazone, who
gained weight (+2.8 kg) (P , 0.05 for
both). Nausea was transient and predom-
inantly mild (24% exenatide QW; 10% si-
tagliptin; 5% pioglitazone); there was one
withdrawal caused by nausea ineach treat-
ment arm. There was no major hypoglyce-
mia. The incidenceofminorhypoglycemia
was low and similar among the treatment
groups (1.3,3.0,and 0.6%ofpatients who
received exenatide QW, sitagliptin, and
pioglitazone, respectively). The incidence
of injection site-related events with exena-
tideQWwaslow(10%)andcomparableto
placebo microshere injection in the sita-
gliptin and pioglitazone groups (7%).
PRO instruments
At baseline and week 26, patients com-
pleted self-report measures of weight-
related QOL, the Impact of Weight on
Quality of Life-Lite (IWQOL-Lite) (17);
health utility, the EuroQol 5 Dimensions
measure (EQ-5D) (18,19); psychological
well-being, the Psychological General
Well-Being Index (PGWB) (19,20); and
diabetestreatmentsatisfaction,theDiabe-
tes Treatment Satisfaction Questionnaire-
status version (DTSQ-s) (21). Patients
were asked to complete the PRO instru-
mentsatthebeginningoftheirclinicvisit,
prior to any procedures. Patients who ter-
minated their participation prior to week
26 were asked to complete the study
questionnaires aspartof their early termi-
nation assessment.
IWQOL-Lite
The impact of weight-related QOL was
assessed with the IWQOL-Lite. The ﬁve
domains of the IWQOL-Lite are physical
function, self-esteem, sexual life, public
distress, and work. Normalized IQWOL-
Lite scores (the total score and separate
scores for each of the ﬁve domains) range
from 0–100, with 0 representing the
worst outcome and 100 representing the
best. The IWQOL-Lite has demonstrated
robust psychometric properties in obese
persons with and without diabetes (17).
EQ-5D
Perceived health status was assessed with
the EQ-5D, a generic measure that
p r o v i d e sas i n g l ei n d e xv a l u et h a tc a nb e
used in clinical and economic evaluation
of health outcomes (18). The EQ-5D has
two parts. The ﬁrst part is a descriptive
systemconsistingofﬁvedimensions:mo-
bility, self-care, usual activities, pain/
discomfort, and anxiety/depression.
Each dimension has three possible levels
(i.e., 1, 2, or 3), representing “no prob-
lems”, “some problems”,a n d“extreme
problems”, respectively. The second part
is a visual analog scale that has end points
labeled “best imaginable health state” and
“worst imaginable health state” anchored
at100and0,respectively.TheEQ-5Dhas
demonstratedgoodreliabilityandvalidity
in patients with type 2 diabetes (19).
PGWB
General psychological well-being was as-
sessed with the PGWB (20). The six di-
mensionsofthePGWB(andscoreranges)
are anxiety (0–25), depressed mood (0–
15), positive well-being (0–20), self-
control (0–15), general health (0–15),
and vitality (0–2 0 ) .Ag l o b a ls c o r e ,c o m -
puted as the sum of the six dimensions,
ranges from 0 to 110. Normalized scores
(the global score and each dimension
score) range from 0 to 100. Higher scores
for each dimension and the global score
indicate higher well-being. The PGWB
hasdemonstratedgoodreliabilityandval-
idity in patients with type 2 diabetes (19).
DTSQ-s
Satisfaction with diabetes treatment was
assessed with the DTSQ-s (21). The
DTSQ-s contains eight items assessing
overall treatment satisfaction, treatment
convenience, treatment ﬂexibility, satis-
faction with understanding of diabetes,
willingness to continue current treat-
ment, willingness to recommend current
treatmenttoothers,frequencyofunaccept-
ably high blood glucose, and frequency
of unacceptably low blood glucose. Re-
sponseoptionsforallitemsareona7-point
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Best and AssociatesLikert scale ranging from 0 (i.e., very dis-
satisﬁed) to 6 (i.e., very satisﬁed). All items
exceptperceivedhypoglycemiaandhyper-
glycemia items are summed to produce a
total treatment satisfaction score. DTSQ-s
totalscoresrangefrom0to36,withhigher
scores indicating higher satisfaction. The
perceived frequency of hyperglycemia
and hypoglycemia items are scored sepa-
rately; lower scores on these two items
represent better perceived blood glucose
control. The DTSQ-s has demonstrated
good reliability and validity in patients
with type 2 diabetes (21).
Statistical analysis
The intent-to-treat population, deﬁned as
all randomized subjects who received at
least one dose of randomized study med-
ication, was used for all analyses. All tests
of treatment effects were conducted at a
two-sided signiﬁcance level of 0.05. The
prespeciﬁed primary analysis of PROs
was to compare the treatment effects
between groups (sitagliptin vs. exenatide
QW, and pioglitazone vs. exenatide QW)
at week 26.
The analysis was based on the
ANCOVA model including factors for
treatment group, country, and baseline
A1C strata (,9v s .$9%), and baseline
PRO score as a covariate. Least squares
means of changes from baseline to week
26andthetwo-sided95%CIsforchanges
at week 26 were derived from the model.
To adjust for multiple comparisons, we
ﬁrst tested between-group differences
for the overall measure from each instru-
ment; tests for subscales were performed
only if the overall score differed signiﬁ-
cantlybetweengroups.Signiﬁcancelevels
were adjusted for multiple comparisons
using Holm’sm e t h o df o r1) between-
group differences in overall scores on
each instrument, 2) between-group differ-
ences in subscale scores within an instru-
ment,and3) testsofchangesfrombaseline
values within each treatment arm.
Missing postbaseline PRO measures
were imputed by the last observation
carried forward method using values
obtained at the time of each participant’s
termination. To check for potential inter-
action between completer status and
treatment arm, changes in the overall
PRO scores were treated as the response
variables.Independentvariablesincluded
treatment group main effect, completer
status main effect, country, baseline A1C
strata(,9vs.$9%),baselinePROscores,
and the interaction term between com-
pleter status and treatment arms. The
main effects by completer status and the
interaction terms were explored.
Statistical analysis was performed us-
ing SAS (8z2; SAS Institute, Cary, NC).
RESULTS—A total of 491 patients
comprised the intent-to-treat population
(160 exenatide QW, 166 sitagliptin, and
165 pioglitazone). Demographic and
baseline clinical variables were similar
between treatment groups (Table 1).
Mean age of study participants was
52–53 years, 48–56% were male, and
30–39% were white, with a mean BMI of
32–33 kg/m
2, a mean A1C of 8.2–8.3%,
andameandiabetesdurationof5–6years.
On entry to the study, participants were
treated with metformin monotherapy.
Effects of exenatide QW treatment
on weight-related QOL
At week 26, IWQOL-Lite total scores and
all separate domain scores had increased
signiﬁcantlyinboththeexenatideQWand
sitagliptin treatment arms (all P , 0.05).
The exenatide QW group experienced sig-
niﬁcantly greater improvement than the
pioglitazone group in total weight-related
QOL;subsequentanalysisrevealedthatthe
exenatide QW group experienced signiﬁ-
cantly greater improvement in public dis-
tress, physical function, and work. There
were no statistically signiﬁcant differences
between the exenatide QW and sitagliptin
groupsintotalweight-relatedQOL,andno
additional between-group tests were con-
ducted.
Effect of exenatide QW treatment
on general health utility
Atweek26,(Table2)EQ-5Dindexscores
and visual analog scores had increased
signiﬁcantly in the exenatide QW and si-
tagliptin treatment groups (all P , 0.05),
but not in the pioglitazone group. There
were no signiﬁcant differences between
groups for change in EQ-5D.
Effect of exenatide QW treatment
on psychological well-being
At week 26, all three treatment groups
experienced signiﬁcant improvements in
all six dimensions of the PGWB (anxiety,
depressed mood, positive well-being,
self-control, general health, and vitality)
and on the PGWB global scale (all P ,
0.05); there were no statistically signiﬁ-
cant differences between exenatide QW
and the other groups for the global scale,
and no additional between-group tests
were conducted.
Effect of exenatide QW treatment
on diabetes treatment satisfaction
At week 26, all three treatment groups
experienced improvements in total
DTSQ-s scores (all P , 0.05). Prior to
adjustment for multiple comparisons, to-
tal DTSQ-s scores improved more in the
exenatide QWgroupthan inthesitagliptin
group (P = 0.041); after adjustment this
difference was not signiﬁcant. All three
groups experienced decreases in per-
ceived frequency of hyperglycemia (all
P , 0.05); there were no statistically sig-
niﬁcant differences between exenatide
Table 1—Baseline demographic and clinical characteristics of intent-to-treat subjects
with type 2 diabetes participating in a 26-week, randomized, multicenter, double-dummy
study of patients treated with exenatide QW, sitagliptin, or pioglitazone
Exenatide QW Sitagliptin Pioglitazone
n 160 166 165
A g e( y e a r s ) ,m e a n( S D ) 5 2( 1 0 ) 5 2( 1 1 ) 5 3( 1 0 )
Sex, n (%)
Male 89 (56%) 86 (52%) 79 (48%)
Female 71 (44%) 70 (48%) 86 (52%)
Race/Ethnicity, n (%)
White 53 (33%) 50 (30%) 65 (39%)
Black 19 (12%) 20 (12%) 13 (8%)
Hispanic 50 (31%) 49 (30%) 44 (27%)
Asian 37 (23%) 42 (25%) 40 (24%)
Other 1 (1%) 5 (3%) 3 (2%)
Weight (kg), mean (SD) 89 (20) 87 (20) 88 (21)
BMI (kg/m
2), mean (SD) 32 (5) 32 (5) 33 (5.5)
A1C (%), mean (SD) 8.6 (1.2) 8.5 (1.2) 8.5 (1.1)
Duration of diabetes (years), mean (SD) 6 (5) 5 (4) 6 (5)
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QOL and treatment satisfaction with exenatideQW and the other groups. There were no
statistically signiﬁcant decreases in per-
ceived frequency of hypoglycemia in any
of the groups and no statistically signiﬁ-
cant differences between exenatide QW
and the other groups.
Effect of attrition on study outcomes
Attrition for the four PROs ranged from
10.74 to 14.39% in the exenatide QW
arm, from 5.04 to 5.76% in the sitagliptin
arm, and from 8.94 to 9.23% in the
pioglitazone arm. The main effect by
completion/attrition status was statisti-
cally signiﬁcant for all overall PRO scores
except IWQOL, with changes in PRO
scores in the dropouts lower than those
of the completers (IWQOL P = 0.05; all
other P values , 0.01). However, the dif-
ferences in PRO score change between
completersanddropoutsdidnotvarysig-
niﬁcantly across treatment arms. Thus,
the last observation carried forward im-
putation did not affect the test for differ-
ence in PRO score change between
treatment groups, which is the main in-
terest of this article.
Potential mediators of effects on
treatment satisfaction
There was no signiﬁcant difference in
total treatment satisfaction in the 40 sub-
jects who experienced nausea and/or
vomiting versus the 190 who did not
(P = 0.80), and the effect did not differ
across treatment arms (P = 0.51) (results
not shown).
We conducted analyses to assess the
correlation between weight change and
changes in weight-related QOL in the
entire study population and in each treat-
ment group. Reduction in body weight
wascorrelatedwithimprovementinover-
all IWQOL scores in the entire study
population (r = 20.26, P , 0.0001).
CONCLUSIONS—Because there are
many treatment options for patients
with type 2 diabetes, data comparing the
effects of treatments can inform choices
among these options. This study com-
paredthreetreatment optionsforpatients
whose blood glucose levels are not ade-
quately controlled on metformin mono-
therapy. These treatment options address
one or both of the clinical issues (hypo-
glycemia and weight) that were raised as
concernsduringintensivemanagementof
patients with type 2 diabetes (14). The
primary outcomes of this study, reported
elsewhere(16),indicatedthatparticipants
in the exenatide QW arm experienced
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Best and Associatesgreater A1C reductions and greater reduc-
tions in weight than participants in the
sitagliptin or pioglitazone arms, that there
was no major hypoglycemia in the exena-
tide QW arm, and that the incidence of
minor hypoglycemia was low and similar
in all treatment groups. This suggests that
exenatide QW treatment provides clini-
cally relevant beneﬁts to patients early in
the disease process. The ﬁndings of the
current study suggest that exenatide QW
treatment also provides beneﬁts across a
broad range of PRO, including general
health utility, weight-related QOL, psy-
chological well-being, and diabetes treat-
ment satisfaction. For some of these
PROs,thebeneﬁtsof exenatideQW ther-
apy were signiﬁcantly greater than the
beneﬁts of sitagliptin or pioglitazone
therapy.
We hypothesized that there would be
PRO advantages for exenatide QW, espe-
cially for PROs likely to be most sensitive
to the known beneﬁts of this agent—the
IWQOL(weight control)and the DTSQ-s
(glycemic control). The PRO advantages
of exenatide QW over the other study
treatmentsweremostnotableforthemea-
sure of weight-related QOL. Patients in
the exenatide QW arm experienced
greater improvements than patients in
the pioglitazone arm on most IWQOL
measures. These ﬁndings are consistent
with the large and statistically signiﬁcant
difference in weight change during the
study in the two arms (22.3 vs. 2.8 kg).
Theassociationofclinicalbeneﬁtssuchas
weight loss with cognate PRO has been
demonstrated in other studies (22). In
this study, the smaller difference in weight
change between the exenatide QW and
sitagliptin arms (22.3 vs. 20.8 kg) was
not associated with a difference between
arms in weight-related QOL.
T h em o r eg e n e r i cQ O Lm e a s u r e s
assessed in the current study—general
health utility and psychological well-
being—showed fewer differences among
treatment arms. Healthutilityimprovedin
the exenatide QW arm and the sitagliptin
arm but not in the pioglitazone arm, and
psychological well-being improved in
all three arms, with no signiﬁcant dif-
ferences among arms on any of these
measures.Asmightbeexpected(6),these
generic measures were less sensitive than
the more speciﬁc measures to differences
in the clinical effects of the study inter-
ventions (glucose control and weight
changes).
The PRO advantages of exenatide QW
were also apparent for diabetes treatment
satisfaction, for which improvement in
DTSQ-s total scores was greater for the
exenatide QW arm than for the sitagliptin
arm. These advantages for exenatide QW
may reﬂect the medication’s greater bene-
ﬁts for both glucose control and weight
control.Earlierstudieshavedemonstrated
the associations of clinical beneﬁts with
treatment satisfaction and treatment pref-
erence (22). However, this study did not
demonstrate differences in patients’ per-
ceptions of the actual group differences
in improved glucose (reduction of hyper-
glycemia), and there was no measure of
the perceived beneﬁt of weight control.
This study is consistent with ﬁndings
that improvements in clinical outcomes
(e.g., glycemic control) in patients with
diabetes are associated with increases in
overall diabetes treatment satisfaction
(23). This study is also consistent with
our earlier report of improved treatment
satisfaction and QOL in patients treated
with exenatide QW and exenatide BID
(9), and with the ﬁnding from that study
that the potential adverse effects of
exenatide treatment (nausea/vomiting),
whichweremorecommonintheexenatide
QW group, did not affect patients’ treat-
ment satisfaction. This suggests that these
adverse effects were not severe enough to
affect patients’ perceptions of the study
medication.
Although the association between
treatment satisfaction and treatment
adherence—a sine qua non for realizing
the potential beneﬁts of a therapy—have
not been demonstrated conclusively, sev-
eral studies suggest that greater treatment
satisfaction is associated with greater
treatment adherence (5,24,25).
Study strengths and limitations
This is the ﬁrst study comparing PRO for
three treatment options that address one
or both of the clinical issues (hypoglyce-
mia and weight) that have been raised as
concernsduringintensivemanagementof
patients with type 2 diabetes (14). In ad-
dition,we assessed a broad range of PROs
usingvalidatedquestionnaireslikelytobe
sensitive to the established clinical effects
of the study medication. The study
included a substantial number of partici-
pants in three countries, and the partici-
pation of ethnic minorities was
reasonably large, so the ﬁndings of this
study are more broadly generalizable
than is often the case. Finally, we were
able to assess the effects of the more com-
monlyreportedmedicationsideeffectson
treatment satisfaction and other PRO.
The double-dummy design of the
current study had advantages and disad-
vantages. An advantage is that it permits a
head-to-head comparison of effects on
PRO that isnot confoundedwithmode of
medication administration, thereby over-
coming one of the problems of studying
PRO in open-label designs comparing
injectable and oral medications. On the
other hand, it makes the comparison of
treatment satisfaction problematic, be-
cause it may have masked any negative
effectsontreatmentsatisfactionassociated
with injection therapy (exenatide QW)
compared with oral therapy (sitagliptin
and pioglitazone).
The lack of a control group with no
change in medication prevents us from
makingdeﬁnitive interpretations of study
ﬁndings. For example, the fact that pa-
tients in all arms reported improvements
in total treatment satisfaction scores de-
spite adding an injection to their treat-
ment regimen could reﬂect the beneﬁts of
improvedglucosecontrolseeninallarms,
oritcouldreﬂectaplaceboeffectresulting
from receiving a change in medication;
thelackofacontrolgroupwithnochange
in medication prevents us from distin-
guishing these alternative explanations.
In addition, the generalizability of the
study ﬁndings is limited by features of all
randomized clinical trial, including in-
tensiﬁed efforts to promote adherence
andretention,theartiﬁcialityofproviding
free intervention and medication (espe-
cially in developing nations), exclusion
criteria, and inﬂuences upon self-selection
such as socioeconomic status and willing-
ness to be in a clinical trial.
Implications for future research
Although the results suggest that exenatide
QW has PRO advantages over sitagliptin
and pioglitazone, it remains to be seen
whether the different medications are pre-
ferred by different patient subgroups.
Systematic evaluation of patient differen-
cesthataccountforalternativepreferences
should be pursued. A comparison of ex-
enatide QW with other potential treat-
ment options is also warranted. Research
to assess potential mediators of the asso-
ciation between exenatide use and PRO,
including the possibility that exenatide
usereducesC-reactiveproteinandnitrous
oxide levels, is also warranted.
Clinical implications
In this study exenatide QW treatment was
associated with important clinical beneﬁts,
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QOL and treatment satisfaction with exenatideincluding improved glucose control and
weight loss (16), and patients previously
treated with metformin monotherapy re-
ported improved weight-related QOL and
highersatisfactionwiththeirstudymedica-
tion regimen than their previous therapy.
Moreover, nausea/vomiting—a side effect
associated with exenatide—did not affect
treatment satisfaction in this study, sug-
gestingthattheseeffectsmightnotbeabar-
rier to patients’ accepting treatment with
these medications.
In combination with earlier ﬁndings
fromthisstudy(16),ourresultsindicateit
is possible for patients treated with met-
formin monotherapy to initiate exenatide
therapy with potential beneﬁts in both
clinical outcomes and PROs.
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